EP1182929A4 - Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues - Google Patents

Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues

Info

Publication number
EP1182929A4
EP1182929A4 EP00937791A EP00937791A EP1182929A4 EP 1182929 A4 EP1182929 A4 EP 1182929A4 EP 00937791 A EP00937791 A EP 00937791A EP 00937791 A EP00937791 A EP 00937791A EP 1182929 A4 EP1182929 A4 EP 1182929A4
Authority
EP
European Patent Office
Prior art keywords
osteonectin
tissues
treatment
gene therapy
toxic gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00937791A
Other languages
German (de)
French (fr)
Other versions
EP1182929A1 (en
Inventor
Leland W K Chung
Chia-Ling Hsieh
Kenneth S Koeneman
Fan Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia UVA
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Publication of EP1182929A1 publication Critical patent/EP1182929A1/en
Publication of EP1182929A4 publication Critical patent/EP1182929A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00937791A 1999-05-28 2000-05-25 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues Withdrawn EP1182929A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13644099P 1999-05-28 1999-05-28
US136440P 1999-05-28
PCT/US2000/014482 WO2000072679A1 (en) 1999-05-28 2000-05-25 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues

Publications (2)

Publication Number Publication Date
EP1182929A1 EP1182929A1 (en) 2002-03-06
EP1182929A4 true EP1182929A4 (en) 2003-04-16

Family

ID=22472869

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00937791A Withdrawn EP1182929A4 (en) 1999-05-28 2000-05-25 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues

Country Status (6)

Country Link
EP (1) EP1182929A4 (en)
JP (1) JP2003500422A (en)
AU (1) AU5291800A (en)
CA (1) CA2374141A1 (en)
IL (1) IL146794A0 (en)
WO (1) WO2000072679A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes
EP2561887B8 (en) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Cancer therapy sensitizer
CA2530748A1 (en) 2003-06-24 2005-02-24 Johns Hopkins University Methylated gene biomarkers for detecting cancer
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AR053246A1 (en) * 2006-04-28 2007-04-25 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM SPARC'S HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
KR20170054429A (en) 2014-09-03 2017-05-17 제네세규스 인코포레이티드 Therapeutic nanoparticles and related compositions, methods, and systems
CN114533959B (en) * 2022-04-02 2022-12-09 山东隽秀生物科技股份有限公司 Tendon repair material, preparation method and application in preparation of tendon repair product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
WO1998029138A2 (en) * 1996-12-27 1998-07-09 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029138A2 (en) * 1996-12-27 1998-07-09 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 2 February 1990 (1990-02-02), retrieved from EBI Database accession no. J04951 *
DATABASE EMBL [online] 20 February 1989 (1989-02-20), retrieved from EBI Database accession no. J04424 *
DATABASE EMBL [online] 29 June 1998 (1998-06-29), XP002230486, retrieved from EBI Database accession no. U65081 *
DATABASE EMBL [online] 5 October 1995 (1995-10-05), XP002230485, retrieved from EBI Database accession no. X82259 *
GARDNER T A ET AL: "Exploiting stromal-epithelial interaction for model development an new strategies of gene therapy for prostate cancer and osteosarcoma metastases (review)", GENE THER MOL BIOL, 7 August 1998 (1998-08-07), pages 41 - 58, XP001135089 *
HAFNER M ET AL: "A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription.", MATRIX BIOLOGY: JOURNAL OF THE INTERNATIONAL SOCIETY FOR MATRIX BIOLOGY. GERMANY DEC 1995, vol. 14, no. 9, December 1995 (1995-12-01), pages 733 - 741, XP009005383, ISSN: 0945-053X *
JENDRASCHAK E ET AL: "Isolation of human promoter regions by Alu repeat consensus-based polymerase chain reaction.", GENOMICS. UNITED STATES 15 MAY 1998, vol. 50, no. 1, 15 May 1998 (1998-05-15), pages 53 - 60, XP002230481, ISSN: 0888-7543 *
NOMURA S ET AL: "Evidence for positive and negative regulatory elements in the 5'-flanking sequence of the mouse sparc (osteonectin) gene.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 25 JUL 1989, vol. 264, no. 21, 25 July 1989 (1989-07-25), pages 12201 - 12207, XP002230483, ISSN: 0021-9258 *
PODHAJCER O L ET AL: "COMPARATIVE EXPRESSION OF THE SPARC AND STROMELYSIN-3 GENES IN MAMMARY TUMOURS", BREAST, EDINBURGH, GB, vol. 5, no. 1, 1 February 1996 (1996-02-01), pages 13 - 19, XP002061778, ISSN: 0960-9776 *
SATYAMOORTHY K ET AL: "Identification of an intronic enhancer that nullifies upstream repression of SPARC gene expression.", NUCLEIC ACIDS RESEARCH. ENGLAND 1 AUG 1997, vol. 25, no. 15, 1 August 1997 (1997-08-01), pages 3169 - 3174, XP002230484, ISSN: 0305-1048 *
See also references of WO0072679A1 *
YOUNG M F ET AL: "Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 5 JAN 1989, vol. 264, no. 1, 5 January 1989 (1989-01-05), pages 450 - 456, XP002230482, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2000072679A1 (en) 2000-12-07
JP2003500422A (en) 2003-01-07
EP1182929A1 (en) 2002-03-06
AU5291800A (en) 2000-12-18
IL146794A0 (en) 2002-07-25
CA2374141A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
GB9903841D0 (en) Diagnosis and treatment of cancer
PL354093A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002243495A1 (en) Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1045332A1 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL146794A0 (en) Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
EP1139750A4 (en) Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU4281200A (en) Immuno-adjuvant pdt treatment of metastatic tumors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030227

17Q First examination report despatched

Effective date: 20040308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040720